However, the routine use of low-dose NSAIDs, glucocorticoids, as well as IL-1 inhibitors for gout prophylaxis is not currently supported by strong evidence [8, 43–46]; therefore, careful consideration of the risks and benefits (i.e., not only evaluation of contraindications) may be clinically relevant in certain populations. Here, IL1A is linked to gout.